



201/12260745/1012



## Directions for Use

B. Braun Melsungen AG · 34209 Melsungen, Germany

# 8.4% Sodium Bicarbonate

### Formulation

1000 mL of solution contain:

Sodium bicarbonate 84.0 g

### Excipients:

Disodium edetate dihydrate, water for injections

### Electrolyte concentrations:

Sodium 1000 mmol/L

Bicarbonate 1000 mmol/L

Theoretical osmolarity 2000 mOsm/L

Titration alkalinity (to pH 7.4) approx. 80 mmol/L

pH 7.0 – 8.5

### Pharmaceutical form

Solution for infusion

### Pharmaco-therapeutic group

Solution for electrolyte substitution

### Indications

- Correction of metabolic acidosis
- Urine alkanisation in the case of intoxication with weak organic acids, e.g. barbiturates or acetylsalicylic acid;
- Urine alkalinisation in order to improve the solubility of drug substances that are poorly soluble in neutral or acid medium, e.g. methotrexate, sulphonamides
- Urine alkalinisation in the case of haemolysis

### Contraindications

8.4% Sodium Bicarbonate must not be administered to patients with

- respiratory and metabolic alkalosis,
- hypernatraemia,
- hypokalaemia.

### Special warnings and precautions for use

8.4% Sodium Bicarbonate should only be administered with particular caution in presence of the following conditions:

- hypoventilation,
- hypocalcaemia,

- increased serum osmolarity,
- further in all situations where sodium intake must be restricted like cardiac insufficiency, oedema, hypertension, eclampsia, severe kidney insufficiency.

Administration of 8.4% Sodium Bicarbonate may lead to sodium and fluid overload.

It must be made absolutely sure that the solution is infused intravenously; accidental intra-arterial infusion may cause shock or loss of an extremity.

Patient monitoring should include regular checks of the acid-base balance, the serum electrolyte concentrations and the water balance.

Correction of the acid-base status is always associated with shifts of the electrolyte balance. In particular, the potassium balance is affected. Alkalisiation or correction of acidosis promote the potassium influx into cells and may therefore lead to hypokalemia.

Potassium or calcium deficiencies should be corrected before beginning of the alkalisating therapy.

### Interactions

Urine alkalisiation by sodium bicarbonate accelerates the elimination of acid drug substances, e.g. acetylsalicylic acid, and delays the elimination of basic drug substances.

Sodium bicarbonate may interact with gluco- and mineralocorticoids, androgens and diuretics increasing the potassium excretion.

Due to their alkaline pH, sodium bicarbonate solutions are incompatible with most medicaments. In particular, they must not be administered simultaneously with solutions containing calcium, magnesium or phosphate because of the possibility of precipitation.

### Dosage

For correction of metabolic acidosis the dose depends on the degree of the disorder of the acid-base status. According to the blood gas values the amount to be administered is calculated according to the following formula:



# B | BRAUN



Schwarz  
148x210 mm  
201/12260745/1012  
Lätus: 1041  
Philippinen





201/12260745/1012

**■ ■ ■ ■ ■** #mL of 1 M (8.4%) sodium bicarbonate solution = base deficit x kg b.w. x 0.3  
**■ ■ ■ ■ ■** (The factor 0.3 corresponds to the proportion of the extracellular fluid in relation to total body fluid).

**■ ■ ■ ■ ■** Example:

If in a patient of 70 kg b.w. the base deficit is 5 mmol/L, then  
 $5 \times 70 \times 0.3 = 105$  mL of 8.4% Sodium bicarbonate are to be given.

Correction of metabolic acidosis should not be effected too rapidly. It is advisable to start administering only half of the calculated dose and adjust further doses according to the actual results of blood gas analysis. For urine alkalization the dose is adjusted according to the desired pH of the urine and administration should be accompanied by monitoring of the acid-base balance and the water balance. Care should be taken not to exceed the maximum infusion rate stated below.

*Maximum daily dose:*

According to the correction requirements.

*Flow rate:*

Up to 1.5 mmol of sodium bicarbonate/kg b.w./h, corresponding to 1.5 mL of solution/kg b.w./h.

*Method of administration*

Intravenous use.

The solution must be infused into a central vein.

**Overdose***Symptoms*

If infused undiluted or too rapidly into peripheral veins, 8.4% Sodium Bicarbonate may cause vein irritation and consecutively phlebitis or thrombosis on account of its alkalinity and its high osmolarity.

Overdose may lead to alkalosis, hypernatraemia, and serum hyperosmolarity. When an acidosis is corrected too rapidly, esp. in cases of concomitant respiratory disorders, the increased liberation of carbon dioxide may transiently aggravate cerebral acidosis.

*Emergency treatment, antidotes*

Therapy of alkalosis, depending on its severity: Infusion of physiological saline, substitution of potassium; for correction of marked alkalosis infusion of arginine hydrochloride or hydrochloric acid.

**Undesirable effects**

Administration of 8.4% Sodium Bicarbonate may lead to hypernatraemia, and serum hyperosmolarity. Paravenous administration may lead to tissue necrosis.

## Note:

Patients are advised to inform their doctor or pharmacist of any adverse effect they experience in connection with the administration of this drug.

**Expiry date**

The product must not be used beyond the expiry date stated on the labeling.

**Instructions for storage/use/handling**

Only to be used if the solution is clear and container undamaged.

The solution is supplied in single-dose containers. Unused portions of the solution must be discarded.

The solution is almost saturated. Do not store above 25 °C. Do not refrigerate or freeze. Possible crystallisation can be reversed by gently warming up the solution.

**Caution**

Foods, Drugs, Devices, and Cosmetics Act prohibits dispensing without prescription.

**Reg. no. :** DR-XY15571

**Manufactured by**

B. Braun Melsungen AG  
 34209 Melsungen, Germany

**Imported by**

B. Braun Medical Supplies, Inc.  
 15th Floor Sun Life Centre  
 5th Ave. cor. Rizal Drive, Bonifacio Global City,  
 Taguig City

**Date of last revision**

12.2010

**B | BRAUN**

B. Braun Melsungen AG  
 34209 Melsungen  
 Germany



Schwarz  
 148x210 mm  
 201/12260745/1012  
 Lätus: 1041  
 Philippinen